MICOFENOLATO MOFETILE CRINOS Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

micofenolato mofetile crinos

crinos s.p.a. - micofenolato mofetile - micofenolato mofetile

BRINZAFLUX Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

brinzaflux

doc generici srl - brinzolamide - brinzolamide

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Unione Europea - italiano - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agenti antitrombotici - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segment elevation infarto miocardico acuto, in combinazione con asa in medicalmente trattati i pazienti eleggibili per la terapia trombolitica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. per ulteriori informazioni, si prega di fare riferimento alla sezione 5.

EFFYDRAL Italia - italiano - Ministero della Salute

effydral

zoetis italia s.r.l. - lattosio, glicina, cloruro di potassio, acido citrico anidro, sodio idrogeno carbonato, cloruro di sodio - lattosio - 32.44 grammo (i) ; glicina - 2.25 grammo (i) ; cloruro di potassio - 1.12 grammo (i) ; acido citrico anidro - 3.84 grammo (i) ; sodio idrogeno carbonato - 6.72 grammo (i) ; cloruro di sodio - 2.34 grammo (i), lattosio - 32.44 g; cloruro di potassio - 1.12 g; sodio idrogeno carbonato - 6.72 g; cloruro di sodio - 2.34 g; glicina - 2.25 g; acido citrico anidro - 3.84 g, lattosio - 32.44 g; cloruro di potassio - 1.12 g; sodio idrogeno carbonato - 6.72 g; glicina - 2.25 g; cloruro di sodio - 2.34 g; acido citrico anidro - 3.84 g - oral electrolytes and carbohydrates

PRAXIS Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

praxis

laboratorio italiano biochimico farmaceutico lisapharma s.p.a. - bicalutamide - bicalutamide

APPRYO Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

appryo

krka d.d. novo mesto - pantoprazolo - pantoprazolo